---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-046340"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2026-07-01T11:17:08+00:00"
generated_at: "2026-07-01T11:20:05.996133+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PBGENE-HBV shows 1-log cccDNA reduction; DMD trial activates second site

## Summary
- PBGENE-HBV in ELIMINATE-B study demonstrated 1-log (10-fold) reduction in cccDNA-derived transcripts from liver biopsy.
- Company targets year-end 2026 for next program update on chronic hepatitis B.
- FUNCTION-DMD trial for Duchenne muscular dystrophy activated second clinical site at Washington University in St. Louis.
- Initial safety data from DMD trial targeted for year-end 2026.

## SEC filing metadata
- accession: 0001628280-26-046340
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2026-07-01T11:17:08+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/0001628280-26-046340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/dtil-20260701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-046340
- JSON: https://secwatch.observer/filing/0001628280-26-046340.json
- Plain text: https://secwatch.observer/filing/0001628280-26-046340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.